An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. (Record no. 13085)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 03838nam a22004697a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 230815s20232023 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 0009-9236 |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1002/cpt.2957 [doi] |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
PMID | 37303270 |
245 ## - TITLE STATEMENT | |
Title | An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. |
251 ## - Source | |
Source | Clinical Pharmacology & Therapeutics. 114(2):275-287, 2023 08. |
252 ## - Abbreviated Source | |
Abbreviated source | Clin Pharmacol Ther. 114(2):275-287, 2023 08. |
253 ## - Journal Name | |
Journal name | Clinical pharmacology and therapeutics |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Year | 2023 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Manufacturer | FY2024 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Publication date | 2023 08 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
Publication status | ppublish |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
Medline status | MEDLINE |
266 ## - Date added to catalog | |
Date added to catalog | 2023-08-15 |
520 ## - SUMMARY, ETC. | |
Abstract | Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases. One of the major barriers to the clinical implementation of cardiovascular pharmacogenetics is limited education on this field for current healthcare providers and students. The abundance of pharmacogenetic literature underscores its promise, but it can also be challenging to learn such a wealth of information. Moreover, current clinical recommendations for cardiovascular pharmacogenetics can be confusing because they are outdated, incomplete, or inconsistent. A myriad of misconceptions about the promise and feasibility of cardiovascular pharmacogenetics among healthcare providers also has halted clinical implementation. Therefore, the main goal of this tutorial is to provide introductory education on the use of cardiovascular pharmacogenetics in clinical practice. The target audience is any healthcare provider (or student) with patients that use or have indications for cardiovascular drugs. This tutorial is organized into the following 6 steps: (1) understand basic concepts in pharmacogenetics; (2) gain foundational knowledge of cardiovascular pharmacogenetics; (3) learn the different organizations that release cardiovascular pharmacogenetic guidelines and recommendations; (4) know the current cardiovascular drugs/drug classes to focus on clinically and the supporting evidence; (5) discuss an example patient case of cardiovascular pharmacogenetics; and (6) develop an appreciation for emerging areas in cardiovascular pharmacogenetics. Ultimately, improved education among healthcare providers on cardiovascular pharmacogenetics will lead to a greater understanding for its potential in improving outcomes for a leading cause of morbidity and mortality. Copyright © 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |
546 ## - LANGUAGE NOTE | |
Language note | English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | *Cardiovascular Agents |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | *Cardiovascular Diseases |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | *Drug-Related Side Effects and Adverse Reactions |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cardiovascular Agents/ae [Adverse Effects] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cardiovascular Diseases/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cardiovascular Diseases/ge [Genetics] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Health Personnel |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Pharmacogenetics/ed [Education] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Indexing | Automated |
656 ## - INDEX TERM--OCCUPATION | |
Department | MedStar Health |
656 ## - INDEX TERM--OCCUPATION | |
Department | Pharmacogenomics |
657 ## - INDEX TERM--FUNCTION | |
Medline publication type | Journal Article |
657 ## - INDEX TERM--FUNCTION | |
Medline publication type | Research Support, N.I.H., Extramural |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Local Authors | Smith, D Max |
Institution Code | MSH |
790 ## - Authors | |
All authors | Aminkeng F, Castrichini M, Cavallari LH, Crews KR, Duarte JD, Friede KA, Hoffecker G, Huang Y, Lteif C, Luzum JA, Murphy WA, Nguyen NHK, Oni-Orisan A, Smith DM, Tantisira K, Tuteja S, Voora D, Whirl-Carrillo M |
856 ## - ELECTRONIC LOCATION AND ACCESS | |
DOI | <a href="https://dx.doi.org/10.1002/cpt.2957">https://dx.doi.org/10.1002/cpt.2957</a> |
Public note | https://dx.doi.org/10.1002/cpt.2957 |
858 ## - ORCID | |
Name | https://orcid.org/0000-0003-3667-2936 |
ORCID text | Smith, D Max |
Orcid | <a href="https://orcid.org/0000-0003-3667-2936">https://orcid.org/0000-0003-3667-2936</a> |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Koha item type | Journal Article |
Item type description | Article |
No items available.